• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
LIU Zhishuang, ZHENG Yufen, SUN Hongna, YU Feng. Effect of Ginkgo biloba extract on anticoagulation of 4 new oral anticoagulants[J]. Journal of China Pharmaceutical University, 2020, 51(3): 327-332. DOI: 10.11665/j.issn.1000-5048.20200310
Citation: LIU Zhishuang, ZHENG Yufen, SUN Hongna, YU Feng. Effect of Ginkgo biloba extract on anticoagulation of 4 new oral anticoagulants[J]. Journal of China Pharmaceutical University, 2020, 51(3): 327-332. DOI: 10.11665/j.issn.1000-5048.20200310
shu

Effect of Ginkgo biloba extract on anticoagulation of 4 new oral anticoagulants

Funds: This study was supported by the Basic Research Foundation of China Pharmaceutical University (No. 2632019PY05)
More Information
  • Received Date: February 18, 2020
  • Revised Date: April 29, 2020
    Graphical Abstract
    • Abstract
  • To explore the effect of Ginkgo biloba extract (GBE) on anticoagulation of 4 new oral anticoagulants (NOACs), dabigatran, apixaban, rivaroxaban and edoxaban in vitro, thrombin time (TT), prothrombin time (PT), activated partial thrombin time (APTT) and the activity of coagulation factor Xa (FXa) of rat plasma were measured at different concentrations of NOACs, GBE or NOACs combined with GBE, respectively. The results showed that TT, PT and APTT were prolonged with the increase of NOACs concentration in the range of 0-500 ng/mL; that except for TT of rivaroxaban, other results showed a good linear correlation with NOACs concentration (r2= 0.78-0.98); and that FXa activity decreased with increased concentration of FXa inhibitors (apixaban, rivaroxaban and edoxaban), with a good linear correlation with concentration of FXa inhibitors in the range of 0-250 ng/mL (r2= 0.85-0.94). GBE had no significant effect on TT, PT and APTT (P>0.05) in the concentration range of 0-500 μg/mL, but FXa activity had a positive linear correlation with GBE concentration (r2= 0.840 4). TT was prolonged with increasing GBE concentration when dabigatran was combined with GBE. When the above FXa inhibitors were combined with GBE, TT shortened and FXa activity increased with rising GBE concentration. There were no significant changes in PT and APTT (P>0.05) when NOACs were combined with GBE. The study results suggest that GBE may synergize with the anticoagulant activity of dabigatran and antagonize the anticoagulant activity of FXa inhibitors, possibly due to its role in increasing FXa activity.
    • FullText(HTML)
    • References (19)
  • [1]
    . Eur Heart J， 2018， 39（16）： 1330-1393.
    [2]
    Tran HA， Gibbs H， Merriman E， et al. New guidelines from the Thrombosis and Haemostasis Society of Australia and New Zealand for the diagnosis and management of venous thromboembolism［J］. Med J Aust， 2019， 210（5）： 227-235.
    [3]
    Saar JA， Maack C， European Society of Cardiology. Diagnosis and management of acute pulmonary embolism. ESC guidelines 2014［J］. Herz， 2015， 40（8）： 1048-1054.
    [4]
    Wang GX， Cao FL， Chen J. Progress in researches on the pharmaceutical mechanism and clinical application of Ginkgo Biloba extract on various kinds of diseases［J］. Chin J Integr Med， 2006， 12（3）： 234-239.
    [5]
    Tian JF， Liu Y， Chen KJ. Ginkgo biloba extract in vascular protection： molecular mechanisms and clinical applications［J］. Curr Vasc Pharmacol， 2017， 15（6）： 532-548.
    [6]
    Li JY， Fang J， Zhong FY， et al. Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of dabigatran etexilate， intermediate metabolite and dabigatran in 50 μL rat plasma and its application to pharmacokinetic study［J］. J Chromatogr B Analyt Technol Biomed Life Sci， 2014， 973C： 110-119.
    [7]
    Gai SC， Huang AL， Feng T， et al. LC-MS/MS method for simultaneous determination of rivaroxaban and metformin in rat plasma： application to pharmacokinetic interaction study［J］. Bioanalysis， 2019， 11（24）： 2269-2281.
    [8]
    He K， Luettgen JM， Zhang DL， et al. Preclinical pharmacokinetics and pharmacodynamics of apixaban， a potent and selective factor Xa inhibitor［J］. Eur J Drug Metab Pharmacokinet， 2011， 36（3）： 129-139.
    [9]
    Ude C， Schubert-Zsilavecz M， Wurglics M. Ginkgo biloba extracts： a review of the pharmacokinetics of the active ingredients［J］. Clin Pharmacokinet， 2013， 52（9）： 727-749.
    [10]
    Chen TR， Wei LH， Guan XQ， et al. Biflavones from Ginkgo biloba as inhibitors of human thrombin［J］. Bioorg Chem， 2019， 92： 103199.
    [11]
    Hirsch GE， Viecili PRN， de Almeida AS， et al. Natural products with antiplatelet action［J］. Curr Pharm Des， 2017， 23（8）： 1228-1246.
    [12]
    Diamond BJ， Bailey MR. Ginkgo biloba： indications， mechanisms， and safety［J］. Psychiatr Clin North Am， 2013， 36（1）： 73-83.
    [13]
    Peng YR， Jiang J， Shen H， et al. Pharmacodynamic study of Ginkgo leaf extract on promoting blood circulation［J］. J China Pharm Univ （中国药科大学学报）， 2003， 34（6）： 77-79.
    [14]
    Parasrampuria DA， Truitt KE. Pharmacokinetics and pharmacodynamics of edoxaban， a non-vitamin K antagonist oral anticoagulant that inhibits clotting factor xa［J］. Clin Pharmacokinet， 2016， 55（6）： 641-655.
    [15]
    Gouin-Thibault I， Flaujac C， Delavenne X， et al. Assessment of apixaban plasma levels by laboratory tests： suitability of three anti-Xa assays. A multicentre French GEHT study［J］. Thromb Haemost， 2014， 111（2）： 240-248.
    [16]
    Bookstaver DA， Sparks K， Pybus BS， et al. Comparison of anti-Xa activity in patients receiving apixaban or rivaroxaban［J］. Ann Pharmacother， 2018， 52（3）： 251-256.
    [17]
    Wolzt M， Samama MM， Kapiotis S， et al. Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux［J］. Thromb Haemost， 2011， 105（6）： 1080-1090.
    [18]
    Katsuura Y， Mochizuki T， Tamura M， et al. Species specificity of anticoagulant activity of activated human protein C： involvement of factor V as well as protein S［J］. Thromb Res， 1996， 82（2）： 147-157.
    [19]
    Fernández JA， Heeb MJ， Xu X， et al. Species-specific anticoagulant and mitogenic activities of murine protein S［J］. Haematologica， 2009， 94（12）： 1721-1731.
    • Related Articles

  • Related Articles

    [1]WANG Zhenghao, GAO Yafeng, ZHANG Lianjun, LIU Chang. Research progress of T cell anti-tumor function regulated by endoplasmic reticulum stress[J]. Journal of China Pharmaceutical University, 2022, 53(5): 518-524. DOI: 10.11665/j.issn.1000-5048.20220502
    [2]JIA Jian, WU Jianbing, ZHANG Yihua, HUANG Zhangjian. Synthesis and protective effect of carboxymethylcysteine L-arginate in bronchial epithelial cells[J]. Journal of China Pharmaceutical University, 2022, 53(2): 171-177. DOI: 10.11665/j.issn.1000-5048.20220206
    [3]CHEN Yingjie, GAO Xiangdong, CHEN Song. Effects and mechanisms of FGF21 on neuronal damage induced by rotenone[J]. Journal of China Pharmaceutical University, 2020, 51(6): 718-723. DOI: 10.11665/j.issn.1000-5048.20200611
    [4]CHEN Suting, CHEN Song, GAO Xiangdong. Construction, expression, purification and neuroprotective activity of TAT-FGF21 fusion protein[J]. Journal of China Pharmaceutical University, 2018, 49(4): 496-501. DOI: 10.11665/j.issn.1000-5048.20180417
    [5]CHEN Jianping, REN Xinsheng, SUN Zhonghua, GUO Zaiyu. Protective effects and mechanisms of breviscapine on endothelial cells[J]. Journal of China Pharmaceutical University, 2015, 46(5): 610-616. DOI: 10.11665/j.issn.1000-5048.20150516
    [6]ZHOU Huana, JIANG Nan, HAN Yuwei, KOU Junping. Advances of the traditional Chinese medicines modulating endoplasmic reticulum stress[J]. Journal of China Pharmaceutical University, 2015, 46(4): 385-392. DOI: 10.11665/j.issn.1000-5048.20150401
    [7]WANG Li, LI Mingdan, LU Yi, ZHANG Chaofeng, XU Xianghong, ZHANG Mian. Mechanism of apoptosis induced by peptide-rich fraction from the root of Aster tataricus in liver L-02 cells[J]. Journal of China Pharmaceutical University, 2014, 45(4): 469-474. DOI: 10.11665/j.issn.1000-5048.20140415
    [8]Effects of MCI-186 on Oxidative Stress-mediated Cell Damage Induced by H2O2 and Reactive Oxygen Species Formation in Brain Neurons[J]. Journal of China Pharmaceutical University, 2004, (6): 84-87.
    [9]WU Yu-Lin, YANG Zheng. Effects of MCI-186 on Oxidative Stress-mediated Cell Damage Induced by H_2O_2 and Reactive Oxygen Species Formation in Brain Neurons[J]. Journal of China Pharmaceutical University, 2004, (6).
    [10]Effects of Crocetin on the Myocardial Cell Damages Due to Oxidative Stress[J]. Journal of China Pharmaceutical University, 2003, (5): 66-69.

  • Cited by

    Periodical cited type(4)

    1. 尹玉君，曹卫平，李卫. 阴道白念珠菌对氟康唑耐药机制的研究进展. 中华临床感染病杂志. 2024(02): 156-160 .
    2. 唐光甫，桂艳玲，满海乔，刘畅，赵杰宏. 红曲桔霉素致毒机理的网络药理学分析. 食品与生物技术学报. 2023(02): 90-96 .
    3. 乔廷廷，王禹，崔玉环，颜娟，郭玲. ERK信号通路在阿尔茨海默病中的研究进展. 医学综述. 2022(03): 422-427 .
    4. 程琛，杨建，秦公照，具晟. 高三尖杉酯碱通过抑制 ERK1/2信号通路逆转卵巢癌细胞顺铂耐药的研究. 川北医学院学报. 2022(12): 1519-1523 .

    Other cited types(5)

Catalog

    Get Citation
    PDF
    XML
    Article views (298) PDF downloads (448) Cited by(9)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：297297

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return